Top cited articles

Acceptance rate


Time to first decision with review

31 days*

Acceptance to publication

14 days*

Impact Factor




2021 DORIS definition of remission in SLE: final recommendations from an international task force
van Vollenhoven, Ronald F.; Bertsias, George; Doria, Andrea; et al

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Tummala, Raj; Abreu, Gabriel; Pineda, Lilia; et al

Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years
Ajeganova, Sofia; Hafstrom, Ingiald; Frostegard, Johan

Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice
Fortner, Karen A.; Blanco, Luz P.; Buskiewicz, Iwona; et al

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
Strand, Vibeke; Simon, Lee S.; Meara, Alexa Simon; et al

Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials
Sun, Fangfang; Geng, Shikai; Wang, Haiting; et al

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA
Bell, Christopher F.; Priest, Julie; Stott-Miller, Marni; et al

Living with systemic lupus erythematosus in 2020: a European patient survey
Cornet, Alain; Andersen, Jeanette; Myllys, Kirsi; et al

Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study
Blazer, Ashira; Dey, Ida Dzifa; Nwaukoni, Janet; et al

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
Merola, Joseph F.; Wang, Wenting; Wager, Carrie G.; et al

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis
Helget, Lindsay N.; Dillon, David J.; Wolf, Bethany; et al

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
Sivakumaran, Jagan; Harvey, Paula; Omar, Ahmed; et al

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
Wang, Huijing; Gao, Yunjie; Ma, Yanhong; Cai, Fanghao; et al

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
Doerner, Thomas; Tanaka, Yoshiya; Petri, Michelle A.; et al

Prediction of prognosis and renal outcome in lupus nephritis
Parodis, Ioannis; Tamirou, Farah; Houssiau, Frederic A.

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
Koelmeyer, Rachel; Tri Nim, Hieu; Nikpour, Mandana; et al

Towards a practical management of fatigue in systemic lupus erythematosus
Mertz, Philippe; Schlencker, Aurelien; Schneider, Matthias; et al

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
Vincent, Fabien B.; Kandane-Rathnayake, Rangi; Koelmeyer, Rachel; et al

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
Nived, Ola; Ingvarsson, Ragnar Frey; Joud, Anna; et al

Associations of metabolic syndrome in SLE
Apostolopoulos, Diane; Vincent, Fabien; Hoi, Alberta; et al